Compare iShares Gold Trust (IAU) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Smith & Nephew plc — how do they compare? iShares Gold Trust trades at $82.87, while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while iShares Gold Trust pays none, and iShares Gold Trust is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| IAU | SNN | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $38.70 |
52-Week Low | $62.49 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU (iShares Gold Trust) trades at $82.76, up 0.3% on the day, with technical indicators showing mixed signals - a bullish moving average trend but overbought RSI levels. The ETF benefits from gold's recent momentum as inflation data aligns with expectations and geopolitical tensions boost safe-haven demand. Recent news highlights gold's strong performance with spot prices reaching $4,438/oz following July CPI data.
The outlook remains positive given gold's defensive characteristics amid economic uncertainty, though overbought technical conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy shifts and dollar strength, while institutional buying and central bank demand provide underlying support.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
